ScreenerHero

FTHFaeth Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · faeththerapeutics.com
32.00USD-3.35%Mkt Cap: 826.89M $P/E: —

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap826.89M $
Enterprise Value643.63M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-21.09M $
Revenue/Share—
Last Price32.00 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.47
PEG—
EV/EBITDA-17.57
EV/Revenue—
P/S—
P/B4.79
EPS (TTM)-59.18
EPS (Forward)-4.96
52W Range
7.21081% of range37.90
52W High37.90 USD
52W Low7.210 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-113.41%
ROA-92.07%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.45M $
CapEx (TTM)16.00K $
FCF Margin—
FCF Yield0.10%
Net Debt-185.85M $
Net Debt/EBITDA5.07
Balance Sheet
Debt/Equity0.08
Current Ratio19.69
Quick Ratio19.46
Book Value/Sh6.695 USD
Cash/Share7.215 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 17, 2025
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)54.50 USD
Upside (mean)+70.3%
Target Range46.00 USD – 60.00 USD
$46.00+70.3% to mean$60.00
# Analysts10
Ownership
Shares Out.25.84M
Float18.55M
Insiders1.44%
Institutions64.43%
Short Interest
Short Ratio3.1d
Short % Float3.21%
Short % Out.3.16%
Shares Short815.59K
Short (prev mo.)780.40K
Technical
SMA 5026.00 (+23.1%)
SMA 20020.26 (+57.9%)
Beta-0.31
S&P 52W Chg18.16%
Avg Vol (30d)312.63K
Avg Vol (10d)283.42K
Technical Indicators
RSI (14)61.0
MACD1.5502
MACD Signal1.1047
MACD Hist.+0.4455
BB Upper33.88 USD
BB Middle28.62 USD
BB Lower23.36 USD
BB Width36.74%
ATR (14)3.214 USD
Vol Ratio (20d)1.51x